OliX PharmaceuticalsI (Korea) Investor Sentiment

226950 Stock   18,960  300.00  1.56%   
About 62% of OliX PharmaceuticalsI's investor base is looking to short. The analysis of current outlook of investing in OliX PharmaceuticalsInc suggests that many traders are alarmed regarding OliX PharmaceuticalsI's prospects. The current market sentiment, together with OliX PharmaceuticalsI's historical and current headlines, can help investors time the market. In addition, many technical investors use OliX PharmaceuticalsInc stock news signals to limit their universe of possible portfolio assets.
  
over three weeks ago at news.google.com         
OliX Pharmaceuticals, Inc Looks Just Right With A 34 percent Price Jump - Simply Wall St
Google News at Macroaxis
over two months ago at news.google.com         
Gilead ends 785M Yuhan deal for small-molecule MASH drugs - BioWorld Online
Google News at Macroaxis
over two months ago at news.google.com         
OliX Pharmaceuticals, Inc Stocks Shoot Up 27 percent But Its PS Still Looks Reasonable - Simply Wall...
Google News at Macroaxis
over three months ago at news.google.com         
Shareholders in OliX Pharmaceuticals have lost 56, as stock drops 16 percent this past week - Simply...
Google News at Macroaxis
over three months ago at news.google.com         
Market Cool On OliX Pharmaceuticals, Incs Revenues Pushing Shares 27 percent Lower - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
BIX 2024 From graveyard to breakthrough, MASH candidates on rise - BioWorld Online
Google News at Macroaxis
over three months ago at news.google.com         
BIX 2024 From graveyard to breakthrough, MASH candidates on rise - BioWorld Online
Google News at Macroaxis
over six months ago at news.google.com         
Its Down 36 percent But OliX Pharmaceuticals, Inc Could Be Riskier Than It Looks - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
OliX Pharmaceuticals, Incs stock price dropped 14 percent last week individual investors would not b...
Google News at Macroaxis
over six months ago at news.google.com         
Even after rising 12 percent this past week, OliX Pharmaceuticals shareholders are still down 65 per...
Google News at Macroaxis
over six months ago at news.google.com         
OliX Pharmaceuticals Full Year 2023 Earnings 1324 loss per share - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
OliX Pharmaceuticals, Incs market cap up 27b last week, benefiting both retail investors who own ......
Google News at Macroaxis
over six months ago at news.google.com         
OliX Pharmaceuticals, Incs market cap up 27b last week, benefiting both retail investors who own 59 ...
Google News at Macroaxis
over six months ago at news.google.com         
OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH - Busin...
Google News at Macroaxis
over a year ago at news.google.com         
OliX Pharmaceuticals Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity D...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about OliX PharmaceuticalsI that are available to investors today. That information is available publicly through OliX media outlets and privately through word of mouth or via OliX internal channels. However, regardless of the origin, that massive amount of OliX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of OliX PharmaceuticalsI news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of OliX PharmaceuticalsI relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to OliX PharmaceuticalsI's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive OliX PharmaceuticalsI alpha.

OliX PharmaceuticalsI Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for OliX Stock analysis

When running OliX PharmaceuticalsI's price analysis, check to measure OliX PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OliX PharmaceuticalsI is operating at the current time. Most of OliX PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of OliX PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OliX PharmaceuticalsI's price. Additionally, you may evaluate how the addition of OliX PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Insider Screener
Find insiders across different sectors to evaluate their impact on performance